1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the surveillance, epidemiology, and end results program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Teicher BA: Searching for molecular
targets in sarcoma. Biochem Pharmacol. 84:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et
al: Neoadjuvant chemotherapy for osteosarcoma of the extremities
with metastases at presentation: Recent experience at the Rizzoli
institute in 57 patients treated with cisplatin, doxorubicin, and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Gorlick R: Current concepts on the
molecular biology of osteosarcoma. Cancer Treat Res. 152:467–478.
2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bruland ØS, Bauer H, Alvegaard T and
Smeland S: Treatment of osteosarcoma. The Scandinavian sarcoma
group experience. Cancer Treat Res. 152:309–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ying HC, Xu HY, Lv J, Ying TS and Yang Q:
MicroRNA signatures of platinum-resistance in ovarian cancer. Eur J
Gynaecol Oncol. 36:16–20. 2015.PubMed/NCBI
|
12
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ziyan W, Shuhua Y, Xiufang W and Xiaoyun
L: MicroRNA-21 is involved in osteosarcoma cell invasion and
migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bi Y, Jing Y and Cao Y: Overexpression of
miR-100 inhibits growth of osteosarcoma through FGFR3. Tumour Biol.
36:8405–8411. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y,
Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration,
invasion, and epithelial-mesenchymal transition in osteosarcoma
cells via targeting Sirtuin 1. Oncol Rep. 34:399–406.
2015.PubMed/NCBI
|
16
|
Wang W, Zhou X and Wei M: MicroRNA-144
suppresses osteosarcoma growth and metastasis by targeting ROCK1
and ROCK2. Oncotarget. 6:10297–10308. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Han K, Chen X, Bian N, Ma B, Yang T, Cai
C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195
suppresses osteosarcoma cell metastasis by targeting CCND1.
Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Du JY, Wang LF, Wang Q and Yu LD: miR-26b
inhibits proliferation, migration, invasion and apoptosis induction
via the downregulation of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven
glycolysis in osteosarcoma cells. Oncol Rep. 33:1890–1898.
2015.PubMed/NCBI
|
19
|
Mao JH, Zhou RP, Peng AF, Liu ZL, Huang
SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell
invasion and migration in vitro by targeting FASN. Oncol Lett.
4:1125–1129. 2012.PubMed/NCBI
|
20
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: A new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ng EK, Chong WW, Jin H, Lam EK, Shin VY,
Yu J, Poon TC, Ng SS and Sung JJ: Differential expression of
microRNAs in plasma of patients with colorectal cancer: A potential
marker for colorectal cancer screening. Gut. 58:1375–1381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Kong X, Du Y, Wang G, Gao J, Gong Y, Li L,
Zhang Z, Zhu J, Jing Q, Qin Y and Li Z: Detection of differentially
expressed microRNAs in serum of pancreatic ductal adenocarcinoma
patients: miR-196a could be a potential marker for poor prognosis.
Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Tsujiura M, Ichikawa D, Komatsu S,
Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi
K, Fujiwara H, et al: Circulating microRNAs in plasma of patients
with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
28
|
Heneghan HM, Miller N, Lowery AJ, Sweeney
KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Cai H, Zhao H, Tang J and Wu H: Serum
miR-195 is a diagnostic and prognostic marker for osteosarcoma. J
Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhang C, Yao C, Li H, Wang G and He X:
Serum levels of microRNA-133b and microRNA-206 expression predict
prognosis in patients with osteosarcoma. Int J Clin Exp Pathol.
7:4194–4203. 2014.PubMed/NCBI
|
31
|
Yuan J, Chen L, Chen X, Sun W and Zhou X:
Identification of serum microRNA-21 as a biomarker for
chemosensitivity and prognosis in human osteosarcoma. J Int Med
Res. 40:2090–2097. 2012. View Article : Google Scholar : PubMed/NCBI
|
32
|
Xue Z, Zhao J, Niu L, An G, Guo Y and Ni
L: Up-regulation of miR-300 promotes proliferation and invasion of
osteosarcoma by targeting BRD7. PloS One. 10:e01276822015.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Yu J, Xie F, Bao X, Chen W and Xu Q:
miR-300 inhibits epithelial to mesenchymal transition and
metastasis by targeting twist in human epithelial cancer. Mol
Cancer. 13:1212014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Zhang D, Yang G, Chen X, Li C, Wang L, Liu
Y, Han D, Liu H, Hou X, Zhang W, et al: mir-300 promotes
self-renewal and inhibits the differentiation of glioma stem-like
cells. J Mol Neurosci. 53:637–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang
N, Zhang Y, Yang B and Wang Z: MicroRNA miR-133 represses HERG K+
channel expression contributing to QT prolongation in diabetic
hearts. J Biol Chem. 282:12363–12367. 2007. View Article : Google Scholar : PubMed/NCBI
|
36
|
Toiyama Y, Takahashi M, Hur K, Nagasaka T,
Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A: Serum miR-21
as a diagnostic and prognostic biomarker in colorectal cancer. J
Natl Cancer Inst. 105:849–859. 2013. View Article : Google Scholar : PubMed/NCBI
|